PRAMOLE XR pramipexole dihydrochloride monohydrate 1.5 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pramole xr pramipexole dihydrochloride monohydrate 1.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; magnesium stearate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PRAMI XR pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

prami xr pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; silicon dioxide; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PRAXOLE XR pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

praxole xr pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; silicon dioxide; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PAMEX XR pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pamex xr pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.75 mg - tablet, modified release - excipient ingredients: hypromellose; silicon dioxide; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PRAMOLE XR pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pramole xr pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3.75 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; calcium hydrogen phosphate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PRAMI XR pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

prami xr pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: hypromellose; silicon dioxide; calcium hydrogen phosphate; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PRAMIPEX XR pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pramipex xr pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.375 mg - tablet, modified release - excipient ingredients: silicon dioxide; magnesium stearate; hypromellose; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PAMEX XR pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pamex xr pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; calcium hydrogen phosphate; hypromellose; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PRAMIPEX XR pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pramipex xr pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: hypromellose; silicon dioxide; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PRAMIPEX XR pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pramipex xr pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; calcium hydrogen phosphate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.